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Abstract: The amount of data collected and managed in (bio)medicine is ever-increasing. Thus,
there is a need to rapidly and efficiently collect, analyze, and characterize all this information. Artificial
intelligence (AI), with an emphasis on deep learning, holds great promise in this area and is already
being successfully applied to basic research, diagnosis, drug discovery, and clinical trials. Rare diseases
(RDs), which are severely underrepresented in basic and clinical research, can particularly benefit
from AI technologies. Of the more than 7000 RDs described worldwide, only 5% have a treatment.
The ability of AI technologies to integrate and analyze data from different sources (e.g., multi-omics,
patient registries, and so on) can be used to overcome RDs’ challenges (e.g., low diagnostic rates,
reduced number of patients, geographical dispersion, and so on). Ultimately, RDs’ AI-mediated
knowledge could significantly boost therapy development. Presently, there are AI approaches being
used in RDs and this review aims to collect and summarize these advances. A section dedicated to
congenital disorders of glycosylation (CDG), a particular group of orphan RDs that can serve as a
potential study model for other common diseases and RDs, has also been included.
Keywords: artificial intelligence; big data; congenital disorders of glycosylation; diagnosis; drug
repurposing; machine learning; personalized medicine; rare diseases
1. Introduction
In Europe, a disease is considered rare when it affects less than 1 in 2000 people [1]. There are
more than 7000 rare diseases (RDs) worldwide [2]. About 80% of RDs have a genetic origin and
approximately 75% affect children [1,2]. Although individually rare, collectively, RDs are estimated to
affect 350 million people globally [3,4].
RDs’ underrepresentation in research and treatment development is related to the following
aspects: (a) underestimation of true disease frequency owing to the lack of RDs’ awareness, as well as
specific diagnostic criteria and official clinical guidelines [5,6]; (b) lack of funding, which hampers basic
and clinical research [6]; (c) small and geographically dispersed patient alongside with the scarcity of
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specific coding systems, which affect patient recruitment for clinical research leading to underpowered
trials [5,7]; (d) insufficient knowledge of the disease pathophysiology and natural history combined
with the insufficiency of validated outcomes and disease-specific biomarkers delays the establishment
of clinical trials [5]; (e) limited interest of pharmaceutical companies associated with the high cost of
drug research and development (R&D) and the small orphan drug market [7].
Despite all of these challenges, the development of new technologies, such as genomic analysis
by means of next generation sequencing (NGS) and other “omics technologies” has boosted RDs’
diagnosis and molecular understanding [8,9]. Information retrieved from these technologies represents
a substantial increase in data that need to be selected, analyzed, and integrated [9]. This “big data” age
constitutes a huge opportunity for the progress of therapy R&D in RDs, but also poses significant data
management and ethical challenges.
Artificial intelligence (AI), mainly through machine learning (ML, a subtype of AI), provides
algorithms capable of learning from data. According to the U.S. Food and Drug Administration, AI is
“the science and engineering of making intelligent machines”, while ML is “an AI tool that can be
used to design and train software algorithms to learn from and act on data” [10]. ML algorithms can
uncover complex data patterns and can be stowed in one of the following categories: (i) supervised
learning (ii), unsupervised learning, or (iii) reinforcement learning [11].
In supervised learning, the data are labeled, that is, the algorithm is given the input data along
with the corresponding target data. The algorithm’s task is then to uncover the relation between inputs
and corresponding targets. Tasks of classification (e.g., whether or not a chest X-ray corresponds to a
tuberculosis patient) [12] and regression (e.g., predicting breast cancer risk from a magnetic resonance
image using logistic regression) [13] are examples of supervised learning.
In unsupervised learning, there are input data, but no targets. The algorithm’s job is to unveil
some underlying structure in the data. The tasks of clustering, which is the automatic assignment
of object groups into clusters (groups) (e.g., study and treatment of Alzheimer’s disease) [14],
and density estimation (e.g., analyzing co-morbidities of migraine) [15] are medical examples of
unsupervised learning.
Finally, in reinforcement leaning, the algorithm’s aim is to find the most suitable action in order to
maximize a reward, which, in turn, depends on the action (e.g., dynamic treatment policies [16] and
epilepsy prevention [17]).
In the last decade, these and other deep learning algorithms proved to be effective in many areas,
leading frequently to state-of-the-art results.
The use of AI algorithms in diagnosis (e.g., analysis and classification of sequence pathogenic
variants) and drug discovery and preclinical research (e.g., new molecules designing, animal
testing reduction, drug interaction) are just some of the examples of the benefits AI has brought
to biomedicine [18]. Most of these tools are applicable to a wide spectrum of diseases, including RDs.
Taking into account all these advances, we aim to understand where we stand as for the use of AI
in RDs. We performed a literature revision, having collected and structured information regarding
the application of AI in several domains of RDs; namely, (a) diagnosis and prognosis, (b) disease
classification and characterization, (c) therapeutic approaches, and (d) patient registries and health
records. Moreover, we highlight AI applications in a specific group of RDs—congenital disorders of
glycosylation (CDG).
This review compiles AI-based tools for biomedical research and clinical practice, increasing the
knowledge and awareness on AI applications in RDs.
2. Materials and Methods
For this review, a double and triple combination of keywords related to RDs and CDG, AI (e.g., ML
and neuronal networks), and medicine/pharmaceutics was used to search the Medline database,
using PubMed as the search engine through its application programming interface (API) Entrez
Programming Utilities [19] (Figures S1 and S2). To use that API, we wrote a Python programming
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language script using libraries from the biopython project [20] (Supplementary Note and Figure S3).
The results for each of the keyword combinations were limited to the twenty most relevant papers.
Duplicate entries were eliminated and a refinement of the results was performed based on the title,
abstract, and MeSH terms of each publication. Three rounds of manuscript selection were performed:
(1) articles were selected based on title and abstract reading by four researchers; (2) the ones matching
the selection criteria were included for the second round of full-manuscript reading; (3) a final round
was performed by two independent researchers, who analyzed all the full-texts, to guarantee uniform
selection criteria of all included manuscripts.
Inclusion/exclusion criteria were as follows:
1. Only English-written manuscripts that included title, abstract, and MeSH terms were selected;
2. Manuscripts expressing the usage of concrete AI algorithms (or families of algorithms) to address
specific problems related to RDs were included;
3. Orphanet classification was adopted and only RDs with Orpha codes were included;
4. Reviews were excluded from the results, although we have included some for contextualization
purposes. References from the included reviews were screened to guarantee that no relevant
manuscripts were missed.
The list of available AI- and ML-based methods found in the included articles can be found in
Table 1.
A classification according to the learning type (unsupervised and supervised), as well as advantages
and disadvantages of the major AI-/ML-based methods described in this review can be found in the
Supplementary Materials (Table S1).
3. RDs’ Prediction: Diagnosis and Prognosis
3.1. Mutation Detection and/or Prediction
The identification of disease-related genes and mutations is essential for diagnosis and disease
prediction [21]. NGS, particularly whole-exome sequencing (WES) and whole genome sequencing
(WGS), is now firmly established in RDs’ diagnostic and research laboratories [22,23]. The advances
made in these technologies make them affordable and indispensable, but the interpretation of the effect
of the discovered new variants remains a challenge [22].
3.1.1. Single Nucleotide Variants
The detection and screening of pathogenic amino acid changes from background polymorphisms
is imperative for efficient use of NGS in personalized medicine [22,24]. Several tools have been created
and used to detect mutations and predict its effects.
Non-synonymous single nucleotide variants (SNVs) that alter protein sequence are strong
candidates for disease-causing variants. Carter et al. described the variant effect scoring tool (VEST),
a new method that uses random forest (RF) to prioritize missense variants that alter protein activity [21].
VEST was applied to Miller and Freeman Sheldon syndromes’ exomes, placing the causal genes among
the top two when only Mendelian genes were considered. The VEST tool is advantageous because
allele frequencies are not required and it performs even without controls [21].
CliniPred, an ensemble classifier for predicting disease relevance of missense SNVs, which uses a
combination of two different ML algorithms (RF and gradient boosting models—Table 1), was applied
to clinical data from 31 different RDs’ exomes, showing a high performance. Furthermore, predictor
performance increased with the addition of allele frequency [22]. SNV prediction methods are generally
sequence-based only or sequence and structure combined. Structure-based features (e.g., binding site)
may act as important determinants for deleteriousness of loci in RDs. However, there has not been an
extensive examination of structure-based features for mutation prediction [25]. Weka, a data-mining
software that contains multiple ML methods to analyze the combination of a RDs’ rare variant dataset
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(ClinVarRVRD) and protein structures from Protein Data Base, has shown that the combination
of structure- and sequence-based features improves rare variant analysis [25]. Synonymous SNVs
may contribute to RDs (e.g., by changing the splicing pattern, as well as protein fold). However,
most pipelines for the identification of disease-causing mutations filter out synonymous SNVs at the
early stages, concentrating on amino acid altering and regulatory variation [26]. Buske et al. have
developed the silent variant analyzer (SilVA), an RF-based prioritization method for synonymous
variants in the human genome. SilVA considers multiple features based on sequence conservation,
splice factor motifs, splice donor/acceptor sites, RNA folding energy, codon usage, and CpG content.
SilVA was used to analyze seven synonymous variants found in Meckel syndrome families and
12 synonymous variants discovered in a group of other RDs. Despite the small number of training
examples, SilVA is a useful method to prioritize synonymous SNVs [26]. A set of supervised learning
tools was used to compare and analyze the effect of variants upon the structure, function, and pathology
of the Mevalonate kinase protein (ORPHA:309025). Three groups (mild, intermediate, and severe)
were obtained, although the discrimination between groups was not sufficient to make meaningful
predictions about variants of unknown severity [27].
A support vector machine (SVM) algorithm was used to predict single nucleotide polymorphisms
(SNPs) significance in common variable immunodeficiency (CVID). Three hundred and sixty-three
CVID patients were genotyped with 610,000 SNPs, with 1000 being strongly predictive of CVID [28].
The analysis of non-and synonymous SNVs using different AI algorithms has proven to be
fundamental for the diagnosis of RDs.
3.1.2. Slicing and Multigenic Mutations
Noncoding regions account for 90% of causal disease loci in genome-wide association studies of
human complex diseases, suggesting that penetrant noncoding variants may be the cause of mutations
in RDs [29]. SpliceAI, a deep residual neural network (NN), predicts the presence and absence of splice
donors and acceptors in pre-mRNA transcripts. It was used to assess the splice-altering impact of a
pathogenic cryptic splice variant in the MYBPC3 intron associated with hypertrophic cardiomyopathy
(ORPHA:217569) [29]. The discovery and analysis of cryptic splice mutations represents a new
diagnostic and therapeutic avenue in RDs.
In RDs, the classic concept of one gene leading to a particular phenotype has been shown
to be an oversimplification. Oligogenic or multilocus genetic patterns have been discovered for
diseases initially considered to be monogenic. Hence, the variant combinations pathogenicity predictor
(VarCoPP), an ML approach to identify pathogenic variant combinations in gene pairs, was developed
by Papadimitriou et al. [30]. VarCoPP was trained using combinations involved in known oligogenic
diseases providing robust 95% and 99% confidence labels. Thus, VarCoPP is a clinically important
tool, making more informative and accurate prediction than those based solely on monogenic variant
pathogenicity scores [30].
3.1.3. Copy Number Variation Analysis
Human copy number variants (CNVs) can cause disease by gene dosage, disruption, g fusion,
or position effects; hence the analysis of CNVs has become routine in genetic diagnosis. Several online
databases and web search services for the analysis of CNVs have been created; however, there is
still the need to search and read the original literature for rare CNVs. Yang et al. employed a
state-of-the-art literature mining method—using DNorm, an ML powered tool that performs named
entities recognition (NER)—to generate CNVdigest, a web-based system containing 1582 CNVs
and 2425 diseases. CNVdigest performs and identifies CNVs-disease associations, and has shown
interesting results in DiGeorge Syndrome (ORPHA:567) [31].
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Table 1. List of available artificial intelligence (AI)- and machine learning (ML)-based methods used in rare diseases (RDs) organized by function.
General
Function Specific Function Reference Software/Platform/Algorithm AI/ML Method Disease(s)
M
ut
at
io
n
D
et
ec
ti
on
an
d
Pr
ed
ic
ti
on
Predicts the
pathogenicity/disease
relevance of
genetic variants
Alirezaie et al.
CADD
https://cadd.gs.washington.edu/ SVM
Several RDs
ClinPred
https://sites.google.com/site/clinpred/
Ensemble classifier (RF and gradient
boosting models)
Yan et al. CNVdigesthttps://github.com/yangxi1016/CNVdigest)
DNorm (conditional random fields,
stochastic gradient descent,
pairwise learning to rank)
Digeorge syndrome
Alirezaie et al.
Fathmm-MKL
http:
//fathmm.biocompute.org.uk/fathmmMKL.htm
SVM based on multiple
kernel learning
Several RDs
GenoCanyon
http://genocanyon.med.yale.edu/ Unsupervised statistical learning
M-CAP
http://bejerano.stanford.edu/mcap/ Gradient boosting trees
MetaLR Ensemble classifier
Meta-SVM Meta-analytic SVM
Browne et al.
Meta-SNP
http://snps.biofold.org/meta-snp/ RF
Mevalonic kinase deficiencynsSNP Analyzer
http://snpanalyzer.uthsc.edu/ RF
PhD-SNP
http://snps.biofold.org/phd-snp/phd-snp.html SVM
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Table 1. Cont.
General
Function Specific Function Reference Software/Platform/Algorithm AI/ML Method Disease(s)
M
ut
at
io
n
D
et
ec
ti
on
an
d
Pr
ed
ic
ti
on
Predicts the
pathogenicity/disease
relevance of
genetic variants
Browne et al. PredictSNPhttp://loschmidt.chemi.muni.cz/predictsnp/
Consensus classifier using the Naïve
Bayes classifier, the multinomial
logistic regression model, NN, SVM,
K-nearest neighbor classifier, and RF
Mevalonic kinase deficiency
Alirezaie et al. REVELhttps://sites.google.com/site/revelgenomics/ RF Several RDs
Buske et al. SilVAhttp://compbio.cs.toronto.edu/silva/ RF Meckel syndrome and other RDs
Browne et al. SNAPhttps://rostlab.org/services/snap2web/ Neural network Mevalonic kinase deficiency
Jaganathan et al. SpliceAIhttps://github.com/Illumina/SpliceAI Deep residual NN
RDs with intellectual disability and
autism spectrum disorders
Alirezaie et al.
VAAST Variant Prioritizer (VVP)
http:
//www.yandell-lab.org/software/vaast.html
Probabilistic search ML tool using
the CLRT Several RDs
Papadimitriou et al. VarCoPPhttps://varcopp.ibsquare.be/ RF
Several RDs (including MODY,
Kallman syndrome, familial
hemophagocytic lymphohistiocytosis,
and nontype I cystinuria)
Carter et al. VESThttps://karchinlab.org/apps/appVest.html RF Miller and Freeman Sheldon syndrome
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Table 1. Cont.
General
Function Specific Function Reference Software/Platform/Algorithm AI/ML Method Disease(s)
M
ut
at
io
n
D
et
ec
ti
on
an
d
Pr
ed
ic
ti
on
Predicts the impact of
SNVs on protein stability,
affinity and functionality
Alirezaie et al. Eigenhttp://eigen.tuxfamily.org/ Unsupervised spectral approach Several RDs
Browne et al.
I-Mutant
http:
//folding.biofold.org/i-mutant/i-mutant2.0.html
SVM
Mevalonic kinase deficiency
iStable
http://predictor.nchu.edu.tw/istable/ SVM
mCSM
http://biosig.unimelb.edu.au/mcsm/ Gaussian process regression model
MUpro
http://mupro.proteomics.ics.uci.edu/ SVM and neural NN
Carter et al.,
Alirezaie et al.,
Browne et al.
PolyPhen2
http://genetics.bwh.harvard.edu/pph2/ Naïve Bayes classifier
Several RDs’ Mevalonic
kinase deficiency
Browne et al. PoPMuSiC-2.1/DEZYMEhttp://dezyme.com/ Simple NN Mevalonic kinase deficiency
Predicts gene/variant
pathogenicity and clinical
relevance while
integrating phenotypic
data
Boudellioua et al.
DeepPVP
https://github.com/bio-ontology-research-
group/phenomenet-vp
Deep NN Several RDs
Bosio et al. eDiVAhttp://www.ediva.crg.eu RF CF, PKU, and other RDs
Li et al. Exomiserhttps://github.com/exomiser/Exomiser RF Several RDs
Li et al. Xrarehttps://web.stanford.edu/~{}xm24/Xrare/ Gradient boosting decision tree Several RDs
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Table 1. Cont.
General
Function Specific Function Reference Software/Platform/Algorithm AI/ML Method Disease(s)
D
ec
is
io
n
Su
pp
or
tS
ys
te
m
s
DDSS based on phenotype
Ronickle et al. AdaDXhttps://ada.com/app/ Augmented QMR Bayesian network Several RDs
(Basel-Vanegaite et al.,
Liehr et al., Zarate et al.,
Marbach et al.,
Martinez-Monseny et al.,
Hsieh et al.
Face2Gene
https://www.face2gene.com Deep NN
RDs including Cornelia de Lange
syndrome, Emanuel syndrome and
Pallister–Killan syndrome,
SATB2-associated syndrome
Rao et al. HANRDhttps://web.rniapps.net/gcas/gcas.tar.gz.
Graph convolution-based association
scoring Several RDs
Jayed et al. Phen–Genhttp://phen-gen.org/ Bayesian network Several RDs
Jia et al. RDADhttp://119.3.41.228:8080/RDAD/faq_help.php
Logistic regression, K-nearest
neighbor, RF, extra
trees, Naïve Bayes, deep NN,
and Bayesian averaging algorithm
Several RDs
Garcelon et al.,
Garcelon et al.
Dr. Warehouse
http://www.drwarehouse.org/ Vector space model
Lowe syndrome, dystrophic
epidermolysis bullosa, activated PI3K
delta syndrome, Rett syndrome,
and Dowling Meara
General
Function Specific Function Reference Software/Platform/Algorithm AI/ML Method Disease(s)
D
is
ea
se
C
la
ss
ifi
ca
ti
on
an
d
M
ec
ha
ni
sm
s’
El
uc
id
at
io
n
Data mining for discovery
of molecular patterns Blasco et al., Lagrue et al.
Biosigner
https://bioconductor.org/packages/release/bioc/
html/biosigner.html
Partial least square discriminant
analysis (PLS-DA), RF, and SVM ALS
N-, O-, and
C-glycosylation sites
prediction
Caragea et al. EnsembleGlyhttps://omictools.com/ensemblegly-tool Ensembles of SVM Possible application in human
disorders of glycosylation
Hamby et al. GPPhttp://comp.chem.nottingham.ac.uk/glyco/ RF
Sub-Golgi proteins
identification Rahman et al.
isGPT
http://77.68.43.135:8080/isGPT/ RF and SVM
Possible application in human
disorders of glycosylation
Data clustering Hoehndorf et al. FLAMEhttps://github.com/zjroth/flame-clustering/ Fuzzy clustering
Several RDs, including LSDs and
Charcot–Marie–Tooth disease 4J
Disease pathways
prediction Taroni et al.
MultiPLIER
https://hub.docker.com/r/jtaroni/multi-plier/ (tag
0.2.0).
Transfer learning
Systemic lupus erythematous,
microscopic polyangiitis, and
(eosinophilic) granulomatosis
with polyangiitis
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Table 1. Cont.
General
Function Specific Function Reference Software/Platform/Algorithm AI/ML Method Disease(s)
D
is
ea
se
C
la
ss
ifi
ca
ti
on
an
d
M
ec
ha
ni
sm
s’
El
uc
id
at
io
n
Prediction models based
on gene expression data
and anatomical
relationships hierarchy
Lee et al. URSAHDhttp://ursahd.princeton.edu./jobs/create/ Bayesian network
Refractory anemia with excessive
blasts and sideroblastic anemia
Data mining, clustering,
and visualization tools Dehiya et al.
Weka
https://www.cs.waikato.ac.nz/ml/weka/ Collection of ML algorithms
Several RDs (they exemplify for CF
and Rett syndrome)
Legend: AI—artificial intelligence; ALS—amyotrophic lateral sclerosis; CADD—combined annotation dependent depletion; CF—cystic fibrosis; CLRT—composite likelihood
ratio test; DDSS—diagnosis decision support system; DeepPVP—deep phenomeNET variant predictor; eDIVA—exome disease variant analysis; GPP—glycosylation predictor;
HANRD—heterogeneous association network for rare diseases; isGTP—identification of sub-Golgi protein types; LSD–lysosomal storage diseases; M-CAP—mendelian clinically applicable
pathogenicity; mCSM—mutation cutoff scanning matrix; ML—machine learning; NER—named entities recognition; NN—neural network; PKU—phenylketonuria; RD—rare diseases;
RDAD—rare disease auxiliary diagnosis; RF—random forest; SilVA—silent variant analyzer; SVM—support vector machine; URSAHD—unveiling RNA sample annotation for human
diseases; VarCoPP—variant combinations pathogenicity predictor; VEST—variant effect scoring tool; SNP—single nucleotide polymorphism; SNV—single nucleotide variants.
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3.1.4. Genotype–Phenotype Integration
An RF model (Table 1) was used to develope eDiVA (exome disease variant analysis), a variant
pathogenicity prediction and annotation tool, which has an innovative pathogenicity classifier
(eDiVA-Score). eDiVA was applied to several RDs (e.g., cystic fibrosis and phenylketonuria,
among others) and identified known causal disease variants with high precision and recall. Interestingly,
prioritization of candidate variants can be enhanced by the addition of clinical information [23].
Both Xrare (using gradient boosting decision tree) and deep phenomeNET variant predictor
(DeepPVP, a deep NN-based tool) prioritize disease-causing variants based on a set of phenotypic and
genetic features. Xrare and DeepPVP outdid other analogous tools (e.g., CADD and Exomiser) and
clinical-expert pipelines at variant prediction [32], even at identifying genes previously unlinked to a
disease [33]. These results suggest that these AI methods may be particularly useful to study RDs and
rare variants [32,33].
In summary, AI and ML methods can efficiently predict disease-causing genes and mutation
types across variable sets of RDs and accounting for different auxiliary measures (e.g., phenotype),
thus accelerating and improving diagnosis accuracy.
3.2. Phenotype and Biochemical Fingerprinting-Driven Diagnosis
Although medicine has entered the genomic era with NGS, the molecular cause of many diseases
is often hard to determine. Hence, clinical phenotype is an invaluable resource for accurate and faster
diagnosis of RDs [4]. Electronic health records (EHR) and biomedical literature contain extensive
clinical information with huge potential in the development of decision support systems (DSS).
3.2.1. Phenotype-Driven Diagnosis
The heterogeneous association network for rare diseases (HANRD) is a phenotype-driven RD
gene prioritization system. It is a network of ontological and curated associations between phenotypes,
diseases, genes and pathways obtained using an information propagation algorithm—graph
convolution-based association scoring—which infers new binary associations between the terms
in the initial network. This tool is a significant advance in diagnosis DSS (DDSS), as it showed better
performance compared with other state-of-the-art tools (Orphamizer) [34]. Paul et al. combined rule
mining and the Dempster–Shafer theory to calculate probabilistic associations between sets of clinical
features and six skeletal dysplasia types recorded in the European Skeletal Dysplasia Network patient
registry. Despite data sparseness, the mixed algorithm outperformed specialist medical diagnosis and
five different ML methods [35]. For Mucopolysaccharidosis type II (MPS II, ORPHA:580) diagnosis
prediction, a naïve Bayes classifier was developed and trained with literature data. The application of
this classifier to an unstructured EHR with 505,526 patients classified 125 as possibly having MPS II
with 99% accuracy and 84% sensitivity [36]. Additionally, a DDSS based on phenotypic information
extraction using collaborative filtering in combination with natural language processing (NLP) was
created. Firstly, it was applied to an EHR database encompassing multiple RDs, afterwards being
improved by the addition of literature mining [37,38]. Ada XD is a promising DDSS prototype using
the augmented Quick Medical Reference (QMR) Bayesian network with an incorporated probabilistic
reasoning engine. Ada XD RD patients’ dataset derives from manually annotated and continuously
updated EHR and medical literature data. In contrast to the aforementioned DDSS, Ada XD does not
require a unique/specific nomenclature (e.g., HPO) [4].
Phen–Gen is a method that uses a systematic Bayesian framework to combine patients’ sequencing
data and symptoms from distinct sources. It has been applied to RDs with highly promising results in
both coding and non-coding variants. It also outranked the accuracy of genotype-only approaches at
variant prediction by 52% [39].
Clinical data warehouses (CDWs) are built on top of EHRs and enable the collection and secondary
use of healthcare data. Dr. Warehouse is an open-source CDW based on a vector space model,
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which explores NLP using the Unified Medical Language System Metathesaurus® (UMLS®) [40].
By leveraging phenotype similarities identified in the EHR, Dr. Warehouse can accelerate RDs’
diagnosis and clinical research recruitment [41].
In summary, the integration of patient information has proven fundamental to accelerating diagnosis.
3.2.2. Imaging-Based DDSS
Many RD patients present characteristic dysmorphology [42]. Images are one of the types of data
that AI, namely deep learning, is more fruitful at analyzing; hence, imaging is crucial in phenotyping,
diagnosis, and even the identification of new RDs [43].
DeepGestalt is a deep learning facial analysis framework for genetic syndromes’ classification
that powers a phenotyping platform named Face2Gene [44]. A crucial feature of deep learning is to
discover abstract representations of the data (in this case, facial images) that highlight attributes that
enable effective learning [45]. The authors use transfer learning to translate the general face recognition
learning trained on a large scale dataset to the rare genetic syndromes’ domain. They conclude
that DeepGestalt can be used to suggest a diagnostic direction in clinical practice. Several studies
have employed DeepGestalt to diagnose rare syndromes with a moderate [46] to high degree of
success, namely, Cornelia de Lange syndrome (ORPHA: 199) [47], Emanuel syndrome (ORPHA:96170),
and Pallister–Killian syndrome (ORPHA: 884) [48]. Besides diagnosis, DeepGestalt can also be applied
to discover new RDs [49].
Other algorithms applied to facial images and neuroimaging have been used to diagnose RDs.
For instance, SVMs have been used with facial images for acromegaly (ORPHA:963) [50] and with
neuroimaging for the prediction of Pick disease (ORPHA:282) and amyotrophic lateral sclerosis
(ALS, ORPHA: 803) presenting with primary progressive aphasia [51].
Hsieh et al. have integrated phenotypic information—generated from AI-based literature and
EHR text-mining and/or from facial imaging analysis—to assist in genetic variant interpretation.
This ingenious approach (called prioritization of exome data by image analysis—PEDIA) was carried
out in a large cohort of patients with monogenetic RDs. The authors show that the addition of
phenotypic data significantly improved correct disease-causing gene prediction, particularly when
deep learning face recognition (with Face2Gene) was encompassed [52].
3.2.3. Biochemical Fingerprinting
Despite the increase of genetic diagnosis in RDs, for several diseases such as hereditary hemorrhagic
telangiectasia (HHT, ORPHA:774), genetic testing is a costly and inefficient option. Lux et al. describe
the use of infrared (IR) spectroscopy allied to artificial NN for HHT diagnosis. Two independent
studies showed the existence of an HHT-specific IR fingerprint. Hence, IR spectroscopy combined
with artificial NN can be considered a serious alternative diagnostic method [53].
In summary, AI can integrate one or several stages of DDSS development: from image recognition
and mining and annotation of phenotypic terms, to disease ranking and prediction and positively
impacting biochemical-driven diagnosis, ascertaining itself as a multifaceted diagnosis enhancer.
3.3. Prognostic Markers
A survival prediction deep learning algorithm (including loss of follow-up cases) was applied in
synovial sarcoma (SS, ORPHA:3273) patients. This novel algorithm achieved better performance than a
conventional NN based on an alive or dead binary classification, as well as that of the Cox proportional
hazard model, the gold standard method for survival prediction in cancers [54]. A complex framework
of AI algorithms, including t-distributed stochastic neighbor embedding clustering, deep NNs
(using principal components analysis (PCA)), RF, k-nearest neighbor, and regulatory networks,
was used in soft tissue sarcomas to identify novel diagnostic and prognostic markers, as well as
potential therapeutic targets. Furthermore, the application of different ML methods has improved
Genes 2019, 10, 978 12 of 24
the understanding of rare cancers [55]. These tools can not only predict disease diagnosis/prognosis,
but also simulate therapeutic options, thus guiding better individualized treatment.
4. Disease Classification and Characterization
4.1. Disease Mechanisms
The unraveling of underlying affected genetic and molecular players and pathways is
crucial for disease comprehension and therapeutic target selection. However, gene expression
anomaly detection and its correlation with molecular mechanisms and clinical phenotypes is a
long-standing ML challenge. The characterizing systematic anomalies in expression (CSAX) data,
which operate with feature regression and classification, were applied to a set of trisomy 18
(ORPHA:3380) samples. CSAX data identified 10 top genes to be related to tooth development,
immune processes, and glucocorticoid metabolism, which is in accordance with the described
clinical phenotype [56]. Small datasets derived from basic research in RDs are challenging for ML.
To overcome this, Taroni et al. resorted to a publicly available gene expression database (recount2)
and trained a pathway-level information extractor matrix factorization framework with multiple
diseases (MuliPLIER). When applied to RDs datasets (specifically systemic lupus erythematosus
(ORPHA:536), granulomatosis with polyangiitis (ORPHA:900), microscopic polyangiitis (ORPHA:727),
and eosinophilic granulomatosis with polyangiitis (ORPHA:183)), MultiPLIER could describe biological
pathways and processes more effectively than the models trained with specific disease datasets [57].
Microarray technology has led to great leaps in molecular disease characterization; nonetheless,
it concomitantly created several analysis and clinical interpretation challenges caused by, for instance,
genomic noise. Biomedical robots are sets of algorithms or classifiers that can analyze data, create new
knowledge, and even act as medical DSS. DeAndrés-Galiana et al. built an AI biomedical robot
(supervised filter feature selection methods and dimensional reduction algorithms) with the goal of
improving microarray analysis sensitivity and knowledge inference. They used this tool in ALS and
inclusion body myositis (IBM, ORPHA:183) patients. In the former, three small-signature genes were
identified with 96.5% accuracy, whereas in the latter, 12 genes (enriched in HLA-x family genes) were
singled out with an accuracy of 97.5%. Additionally, the biomedical robot could distinguish IBM
and polymyositis (ORPHA:732) with 100% accuracy. On the basis of these small-signature genes,
various signaling pathways were suggested to be involved in the pathophysiology of these RDs [58].
In another attempt to tackle noise in microarray reading, authors used microarray synthetic modeling to
compare different gene ranking methods (fold change, Fisher’s ratio, percentile distance, and entropy)
and significance analysis of microarrays. They used the aforementioned ALS and IBM datasets and
concluded that the Fisher ratio was the most precise method with the highest discriminatory power [59].
Gaucher disease (ORPHA:355) is caused by lysosomal enzyme glucocerebrosidase-1 deficiency.
Aggregating molecular dynamics and deep learning (convolutional variational autoencoder), a model
of interaction between this protein and its chaperone-saposin C was designed. This model also
predicted how disease-causing mutations destabilize this interaction, uncovering a relevant disease
mechanism [60]. Exploring the potential of unsupervised deep ML (DeepNEU) to create a cellular
disease model, Danter et al. successfully developed in silico induced neuronal pluripotent stem cells for
Rett syndrome (ORPHA:778) [61]. This in silico approach is cost-effective and may have tremendous
implications in disease pathways and therapeutic target clarification. Different AI and ML methods
allow for the study and prediction of disease mechanisms at distinct levels: from gene to protein
and cells.
4.2. Disease Categorization and Characterization
The lack of data, complexity and heterogeneity within and among RDs, and overlapping and
infrequent clinical manifestations challenge correct disease classification. Often, disease classification
consists of numerous, sequential, and expensive clinical and laboratorial tests. AI and ML represent
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solutions to detect and learn low frequency patterns, delivering automated class attribution,
which facilitates correct treatment recommendation.
The characteristic feature mining algorithm (CFML) has uncovered the key features of 15 bone
dysplasia disorders resorting to the European skeletal dysplasia network. Although this algorithm
showed relatively low average precision (26.73%) and recall (24.68%), it still outdid a standard
algorithm for class association rule mining. Furthermore, the CFML selected hallmark features were
discriminative in 12 of the 15 disorders [53]. More recently, a stochastic gradient boosting narcolepsy
type 1 (ORPHA:2073) versus type 2 (ORPHA:83465) classifier was set up using the European narcolepsy
network data. It identified 15 influential predictors (99% accuracy, sensitivity, and specificity), with some
of them not included in the current narcolepsy classification criteria. Importantly, revisiting the only
misclassified case uncovered a previously incorrect clinician-made diagnosis.
An RF model was used to classify acute liver failure (ORPHA: 90062), determine its etiology,
and improve diagnosis in the clinic, achieving an 80% accuracy score in the etiology assignment.
Bayesian comorbidity networks and subsequent random walk clustering have been used to discriminate
and cluster pediatric pulmonary hypertension (PH, ORPHA:182090) subtypes. Furthermore,
Bayesian comorbidity networks were capable of distinguishing rare subtypes and comorbidity
associations, even suggesting the existence of a previously unidentified subtype with neurological
involvement. In patients with juvenile idiopathic arthritis (ORPHA:92), an identical framework
stratified patients according to clinical and laboratorial pattern recognition. Probabilistic PCA and
Gaussian mixture model clustering using Bayesian information criterion were applied to categorize
the meaningful clinical and biological patterns and to cluster patients, respectively. The originated
five subpopulation clusters were clinically relevant and strongly predictive of disease evolution.
A semantic text-mining approach using PhenomeNET to compute and predict phenotype-disease
relations of 6000 diseases was created. Following this, disease–disease similarity cluster networks
based on phenotypic features were built employing the parameter-free clustering algorithm FLAME.
Interestingly, phenotypic relationships joined several lysosomal storage diseases (LSD) and, in their
vicinity, identified two forms of spinal muscular atrophy, a phenotype not commonly associated with
LSD. However, a patient with Charcot–Marie–Tooth disease type 4J (ORPHA: 139515) presenting LSD
symptomatology was described [62]. Thus, besides improving disease classification, this AI-based
methodology may help diagnose rarer disease (sub)types.
A distinct approach towards phenotype elucidation for better disease comprehension entails the
use of deep learning methods to clarify the relationship between disease and disability. Deep NNs
were applied to a corpus of scientific abstracts manually annotated for disability-related terms in RDs.
This methodology not only detected disability-related terms with an 81% F-measure, but also—via
unsupervised learning—established a relationship between disabilities and diseases with 75% accuracy.
5. Therapeutic Approaches
Currently, only approximately 5% of the RDs have a treatment [8]. AI presents as a potential
game-changer in this field, backed up by the encouraging results obtained in treatment discovery in
common disorders.
5.1. Drug Repositioning
Drug repositioning—a strategy to identify new therapeutic uses for approved or investigational
drugs—has been gaining momentum as a quicker, safer, and cheaper approach, particularly in RDs.
AI has emerged as a highly attractive tool to boost drug repurposing for RDs. Lee et al. utilized an ML
unified computational framework, URSAHD (unveiling RNA sample annotation for human diseases),
which integrates genetic and molecular information about thousands of complex disorders, to test drug
repurposing. On the basis of hallmark processes and mechanistic similarities among common/treatable
and rare/untreatable diseases, URSAHD was able to predict cisplatin as a therapeutic agent to refractory
anemia with excess blasts (ORPHA: 86839) and resveratrol as a potential candidate for sideroblastic
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anemia (ORPHA:1047) treatment [63]. The prediction made by algorithms in both studies must be
experimentally validated and, even though there is still much room for improvement, AI can act as a
drug discovery enhancer.
5.2. Clinical Trials
Clinical trials (CTs) are pivotal for therapy development. Nonetheless, only a small fringe
of RDs have CTs owing to (i) difficulty in patient identification and recruitment; (ii) challenges
associated with data obtention and analysis in small populations; and (iii) lack of reliable biomarkers,
among others [64–66]. AI may provide solutions for these obstacles of CTs in RDs.
5.2.1. Patient Recruitment and Identification
The application of four data mining computable phenotype algorithms to EHR identified 413 new
pediatric patients with PH. Other major advantages of this methodology are that (i) it allows for
continuous patient recruitment and (ii) once validated, it is transferable to other settings [67].
5.2.2. Biomarkers
Reliable biomarkers help in the identification of normal versus pathogenic processes and/or in
the assessment of the response to therapeutics or other interventions, being essential for therapy
development [68,69]. In an olesoxime trial for ALS, the application of the Biosigner algorithm
(using partial least square discriminant analysis, RF, and SVM) to a pharmacometabolic approach
discerned differences in the metabolic profiles between the control and treatment arms. It also
recognized sphingomyelins as the most relevant disease progression marker [70]. Moreover, in West
syndrome (ORPHA:3451) patients, the employment of this algorithm identified serine and an unknown
metabolite (X363) as potential disease biomarkers [71]. Hence, the prediction of disease progression
from early metabolomic profiles allied to pharmacometabolomics represent a promising avenue for
biomarker detection.
Carlier et al. designed an innovative in silico clinical trial to test bone morphogenetic protein
treatment in congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1
(ORPHA:636). Ward hierarchical clustering was employed to stratify the virtual subject population
in adverse responders, non-responders, responders, and asymptomatic. Additionally, an RF-based
algorithm predicted potential biomarkers for therapy effectiveness, namely rate of cartilage formation
(Pmc) and Y3cb [72]. All in all, AI-based methods can resolve many challenges associated with clinical
trials in RDs, particularly in combination with other expanding fields like systems biology.
6. Patient Health Registries and Medical Records
With the exponential growth of patient data in health records and patient registries, more and
better NER methods are indispensable. NER is the process of identifying various semantic classes of
terms (e.g., genes, proteins, and diseases) in raw text. It is the first step in the process of knowledge
discovery and data mining. Nevertheless, for RDs, challenges arise owing to the rarity of the conditions,
complex nomenclatures, and coding or tagging inconsistency between documents or databases.
Additionally, author-specific medical terms, abbreviations, and grammatical errors in EHR further
hinder biomedical NER. Recurrent NNs proved to be advantageous for automated clinical coding
improving representation of RDs in hierarchically-structured medical knowledge [73]. For disease
NER, Bhasuran et al. implemented a stacked ensemble approach combined with fuzzy matching using
both forward and reverse disease labeling. Additionally, they developed an in-house disease dictionary
combining several databases and increasing RD representation. By including the reverse model,
they identified RDs with intricate names unidentified by other NER methods [74]. More recently,
Xu et al. developed Dic-Att-BiLSTM-CRF (DABLC), a deep attention NN method. By incorporating
dictionary-based (using disease ontology) and document-based attention mechanisms, this new method
outperformed existing ones at identifying rare and complex disease names [75].
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This enhancement of RD coding and tagging, as well as their representation in databases,
potentially benefits data/platform interoperability. Indeed, the lack of compatibility between registries
hampers the use of patient data for clinical research. With the goal of contributing to the future
interconnection between registries, cluster analysis and RF were used to analyze patient registries.
Three types of registries with different profiles and informative needs were recognized, namely,
public health, clinical and genetic research, and treatment focused [76].
While important advances are occurring in disease NER using AI, models addressing longer
sentences are needed to improve complex RDs’ recognition. Nevertheless, this progress is not only
optimizing RD annotation and recognition, but also paving the way to platform interoperability.
7. AI for CDG
CDG (ORPHA:137) represents a large heterogeneous group of mostly autosomal recessive disorders
with impaired synthesis and attachment of glycans to proteins and lipids [77], and defects in the synthesis
of glycosylphosphatidylinositol anchors [77–79]. Presently, CDG counts over 130 genetic disorders [80],
with PMM2-CDG (ORPHA:79318) being the most common N-glycosylation disease [81]. Owing to the
fundamental role of glycosylation in a variety of cellular, developmental, and immunological processes,
CDG patients often show multiorgan involvement and elevated phenotypic variability [80,82–85].
As for other RDs, AI has been used to improve research, diagnostics, and therapeutic options search
in CDG.
7.1. AI for CDG Disease Mechanisms Elucidation
7.1.1. Prediction of Glycosylation Sites
The nature of the chemical linkage between specific acceptor residues in the protein and sugar
determines the type of glycosylation; hence, there is a variety of possibilities for the location of
glycosylation sites within a protein [82]. The need for more accurate glycosylation sites’ prediction
has been pushed by the growing data obtained from genomics and other “omics”. The reliability
of this prediction is essential to guide experimental investigations [82]. However, the experimental
determination of glycosylation sites in proteins is an expensive and laborious process [82,83]. Hence,
a glycosylation prediction program (GPP), using an RF algorithm and pairwise patterns, was created [83].
Putative glycosylation sites in glycoprotein sequences were automatically identified using ensembles
of SVM classifiers (Table 1) [82]. Data incorporation from high throughput glycomics and proteomics
projects will foster the development of models that can predict the spatial and temporal dynamics
of protein glycosylation. This can have a significant impact in basic and clinical research, ultimately
improving CDG patients’ quality of life [82,83].
7.1.2. Identification of Golgi Proteins
The Golgi apparatus (GA) is a central hub for membrane trafficking and a fundamental
player in post-translation modifications, particularly in glycosylation. Glycosylation is dependent on
membrane trafficking for proper localization of its machinery and to bring the substrates for further
processing [86,87]. Membrane trafficking at the GA is regulated by several protein complexes, with the
conserved oligomeric Golgi (COG) complex being the most important [88]. Defects and/or malfunction
of the COG complex are responsible for COG-CDG [88]. Hence, the exact classification of GA proteins
may advance diagnosis and basic research, and contribute to targeted drug development in CDG.
The identification of the sub-Golgi protein types (isGPT) model using RF and SVM has been developed
to accurately identify sub-Golgi protein types, namely trans- and cis-Golgi proteins [89].
7.2. AI for CDG Diagnosis, Classification, and Characterization
One of the major pitfalls in CDG is accurate and timely diagnosis [90]. Face2Gene was used to
analyze facial photos of a cohort of 31 PMM2-CDG patients. The trained algorithm correctly identified
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the 31 facial photographs of PMM2-CDG patients and 41 photographs of new patients with a confirmed
PMM2-CDG diagnosis. In all cases, PMM2-CDG appeared in the top 10 syndrome matches offered by
the tool. A recognizable facial pattern in PMM2-CDG patients was identified and three different age
groups (0–5, 6–11, and 12–18) of PMM2-CDG patients were also differentially discriminated [90].
The phenotype-based rare disease auxiliary diagnosis (RDAD) system was used to assist
clinicians in the diagnosis of 27 RDs, including PMM2-CDG. RDAD combines four diagnostic
models, which successfully ranked the most likely candidate RDs in the top 10 [91]. Thus, these tools
could be of added value to PMM2-CDG diagnosis and natural history definition.
Consensus clinical classification is essential for disease characterization and diagnosis. Regarding
EXT1-CDG and EXT2-CDG (multiple osteochodromas; ORPHA:321), no taxonomical system was
consistent or easy to apply [92]. Using a pioneering ML model (switching NN), 150 variables from
189 patients were analyzed. The resulting classification system followed up disease progression and
defined homogenous cohorts of patients, providing insights into disease pathogenesis and helping
diagnosis [92]. Strokes and stroke-like episodes (SLEs) are typical manifestations of CDG [93,94].
SLEs are commonly triggered by infections and have been described in about 20–55% of PMM2-CDG
patients. The underlying pathomechanisms of SLEs are poorly understood and clinical guidelines are
missing [94]. EHRs of 552,898 patients were divided into two age groups (young and old) and analyzed
using data augmentation with active-learning selection to predict young stroke [95]. This model was
not used in RDs or CDG, but it could be easily transferrable to CDG patients, contributing to better
disease management and quality of life.
7.3. AI for Therapy Discovery in CDG
Monogenic RDs can be viewed as dosage problems caused by loss- or gain-of-function of
a gene, usually altering protein activity. mRNA modeling is a potential strategy to repurpose
drugs for these disorders. Connectivity map (https://www.broadinstitute.org/cmap/) and causal
reasoning engine were used to search and analyze mRNA “responsiveness” to drugs in 76 RDs,
among which were SLC38A9-CDG (ORPHA: 468699), MAN2B1-CDG, and PMM2-CDG [96].
Among the 75 genes × 310 drugs analyzed, 119 different putative drug–gene interactions were
identified. Idarubicin showed modest induction of MAN2B1 mRNA expression in fibroblasts [96].
Despite the need for validation of the identified in silico leads in pathophysiologic relevant tissues,
these exciting developments have great potential for revolutionizing the CDG therapeutic landscape.
8. Discussion and Conclusions
In the “big data” era, there is a growing need to automate tasks that currently require human
intervention. In biomedicine, AI technologies have been developed to analyze a diverse array of data,
from individual clinical phenotypes in EHR to large and multiparametric patient cohort analysis,
attenuating outstanding difficulties in RDs [97].
Medical DSS are computer-based systems that can structure, store, and apply medical knowledge
to guide diagnosis and treatment selection. Their application to diagnosis in clinical practice serves
three main purposes: (1) to expedite diagnosis; (2) to correct misdiagnosis; and (3) to diagnose
previously undiagnosed patients [98,99]. Although various DDSS exist, few use AI in their functioning
or methodology. Fewer still focus on RDs, as they pose a bigger challenge owing to phenotypic
heterogeneity and information scarcity. Proof of the existence of such gap is the low exome sequencing
diagnostic yield in RDs (~25–30%) [29]. AI algorithms performing mutation detection, prediction,
and classification can take RDs’ diagnosis to the next level, increasing these figures and uncovering new
disease mechanisms and therapeutic targets. Also, As genomic data alone are frequently insufficient
to diagnose and characterize RD patients, AI-based multi-omics integrative approaches are being
adopted [21–23,25,26,28]. Despite these advances, there is room for improvement in AI-mediated
diagnosis. For instance, existing splice classifiers normally have insufficient specificity because
they focus on local motifs and largely do not account for long-range specificity determinants [29].
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Additionally, as multi-omics data are highly heterogeneous, AI strategies performing network-based
approaches are required to further promote combinatory analysis of big data [97].
DFs can be distinctive characteristics of RDs, including CDG. Their analysis through image-based
DDSS represents a useful and reliable tool [44,51,90]. However, designing and training these models in
RDs faces various confounding and detrimental factors, such as small patient cohorts and differences
in patient ethnicity. Because a high number of relatively homogeneous images are needed to optimize
the model, these limitations may lead to erroneous calculations and/or recommendations [97].
The colossal, dispersed, unstructured, and poorly annotated clinical information presented across
medical literature, EHRs, and patient registries worldwide constitutes a greatly untapped resource.
Recently developed ML tools to analyze heterogeneous, sparse, and noisy clinical data have shed
light on this neglected topic [73–76,97]. Nevertheless, most advances have occurred in unconcerted
actions or in disease niches. Efforts for unified ontologies are needed to implement compatible and
interconnected health registries. AI, through NER and NLP exploration, may play a relevant role in
this field.
We have listed several examples of how AI has boosted therapeutic development in RDs.
These entail the identification of disease biomarkers [70–72], the increase of patient recruitment for
CTs [67], and the discovery of drugs for repurposing [63]. However, much is still to be done to overturn
the low rate of R&D for RDs. AI progress in therapy development has been modest in comparison with
that in other areas (e.g., diagnosis). However, we believe that the stimulating results obtained so far
associated with the ever-evolving AI frameworks will soon change this scenario. Healthcare, research,
and clinical development should be patient-centered [65]. Efforts to increase patient involvement in
various fields of healthcare show a growing need to proactively engage with patients [100], and patient
organizations have a central role to play [101]. AI technologies can help assess patients’ experience
through the analysis of patient reported outcomes and increase patient recruitment and engagement
through social media [100,102]. Furthermore, it can be used to monitor patient adherence in CTs [17].
Despite how much AI predictions pitch in to solve RD medical challenges, all results must be
experimentally validated to confirm their (bio)medical relevance [17]. Additionally, we would like to
emphasize that, for the application of AI in biomedicine, there is no “one size fits all” solution. Biomedical
data/issues are complex; AI-based algorithms and methods are numerous and ever-improving. Also,
technical and technological limitations must be carefully considered when designing an AI approach
in the biomedical context. Our study has some limitations. Firstly, we only searched a Medline
database—Pubmed. Although it is the most complete biomedical literature database, insightful data
present in other databases may have been lost. Secondly, some of the included manuscripts were not
detected in our initial keyword search. This was because of the absence of the keywords related to AI
and ML in both the MeSH terms and in the author-defined keywords of the manuscripts.
Healthcare, research, and patient involvement in health decisions are suffering undeniable change.
We believe it is important to cease this momentum and further explore AI potentialities to improve RDs
patients’ lives. Having said this, many considerations, including ethical and legal issues (e.g., regarding
data management, protection, and access equity), need to be carefully investigated to ensure we will
build a brighter future.
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Abbreviations
AI Artificial intelligence
ALS Amyotrophic lateral sclerosis
API Application programming interface
CDG Congenital disorders of glycosylation
CDWs Clinical data warehouses
CFML Characteristic feature mining algorithm
CNVs Copy number variants
COG Conserved oligomeric Golgi
CSAX characterizing systematic anomalies in expression data
CTs Clinical trials
CVID Common variable immunodeficiency
DABLC Dic-Att-BiLSTM-CRF
DeepPVP Deep phenomeNET variant predictor
(D)DSS (Diagnosis) decision support systems
eDIVA Exome disease variant analysis
HER Electronic health records
GA Golgi apparatus
GPP Glycosylation prediction program
HANRD Heterogeneous association network for rare diseases
HHT Hereditary hemorrhagic telangiectasia
IBM Inclusion body myositis
IR Infrared
isGPT identification of sub-Golgi protein types
LSDs Lysossomal storage diseases
ML Machine learning
MPS II Mucopolysaccharidosis type II
NER Named entities recognition
NGS Next generation sequencing
NLP Natural language processing
NN Neural network
PCA Principal component analysis
PH Pulmonary hypertension
QMR Quick Medical Reference
RDAD Rare disease auxiliary diagnosis system
RDs Rare diseases
R&D Research and development
RF Random forest
SilVA Silent variant analyzer
SLE Stroke-like episodes
SNPs Single nucleotide polymorphisms
SNVs Single nucleotide variants
SS Synovial sarcoma
SVM Support vector machine
URSAHD Unveiling RNA sample annotation for human diseases
VarCoPP Variant combinations pathogenicity predictor
VEST Variant effect scoring tool
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WGS Whole genome sequencing
References
1. Sernadela, P.; González-Castro, L.; Carta, C.; van der Horst, E.; Lopes, P.; Kaliyaperumal, R.; Thompson, M.;
Thompson, R.; Queralt-Rosinach, N.; Lopez, E.; et al. Linked Registries: Connecting Rare Diseases Patient
Registries through a Semantic Web Layer. BioMed Res. Int. 2017, 2017, 1–13. [CrossRef]
2. Ekins, S. Industrializing rare disease therapy discovery and development. Nat. Biotechnol. 2017, 35, 117–118.
[CrossRef] [PubMed]
3. About Rare Diseases. Available online: https://www.eurordis.org/about-rare-diseases (accessed on
18 September 2019).
4. Ronicke, S.; Hirsch, M.C.; Turk, E.; Larionov, K.; Tientcheu, D.; Wagner, A.D. Can a decision support system
accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study.
Orphanet J. Rare Dis. 2019, 14, 69. [CrossRef] [PubMed]
5. Nestler-Parr, S.; Korchagina, D.; Toumi, M.; Pashos, C.L.; Blanchette, C.; Molsen, E.; Morel, T.; Simoens, S.;
Kaló, Z.; Gatermann, R.; et al. Challenges in Research and Health Technology Assessment of Rare Disease
Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value Health 2018, 21, 493–500.
[CrossRef] [PubMed]
6. Stoller, J.K. The Challenge of Rare Diseases. Chest 2018, 153, 1309–1314. [CrossRef]
7. Ahmed, M.A.; Okour, M.; Brundage, R.; Kartha, R.V. Orphan drug development: The increasing role of
clinical pharmacology. J. Pharmacokinet. Pharmacodyn. 2019, 46, 395–409. [CrossRef]
8. Kaufmann, P.; Pariser, A.R.; Austin, C. From scientific discovery to treatments for rare diseases—The view
from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research. Orphanet J.
Rare Dis. 2018, 13, 196. [CrossRef]
9. Schee genannt Halfmann, S.; Mählmann, L.; Leyens, L.; Reumann, M.; Brand, A. Personalized Medicine:
What’s in it for Rare Diseases? In Rare Diseases Epidemiology: Update and Overview; Posada de la Paz, M.,
Taruscio, D., Groft, S.C., Eds.; Springer International Publishing: Cham, Switzerland, 2017; Volume 1031,
pp. 387–404, ISBN 978-3-319-67142-0.
10. Toh, T.S.; Dondelinger, F.; Wang, D. Looking beyond the hype: Applied AI and machine learning in
translational medicine. EBioMedicine 2019, 47, 607–615. [CrossRef]
11. Bishop, C.M. Pattern Recognition and Machine Learning; Information Science and Statistics; Springer: New York,
NY, USA, 2006; ISBN 978-0-387-31073-2.
12. Pasa, F.; Golkov, V.; Pfeiffer, F.; Cremers, D.; Pfeiffer, D. Efficient Deep Network Architectures for Fast Chest
X-Ray Tuberculosis Screening and Visualization. Sci. Rep. 2019, 9, 6268. [CrossRef]
13. Portnoi, T.; Yala, A.; Schuster, T.; Barzilay, R.; Dontchos, B.; Lamb, L.; Lehman, C. Deep Learning Model
to Assess Cancer Risk on the Basis of a Breast MR Image Alone. Am. J. Roentgenol. 2019, 213, 227–233.
[CrossRef]
14. Alashwal, H.; El Halaby, M.; Crouse, J.J.; Abdalla, A.; Moustafa, A.A. The Application of Unsupervised
Clustering Methods to Alzheimer’s Disease. Front. Comput. Neurosci. 2019, 13, 31. [CrossRef] [PubMed]
15. Yang, M.-H.; Yang, F.-Y.; Oyang, Y.-J. Application of density estimation algorithms in analyzing co-morbidities
of migraine. Netw. Model. Anal. Health Inform. Bioinform. 2013, 2, 95–107. [CrossRef] [PubMed]
16. Lunceford, J.K.; Davidian, M.; Tsiatis, A.A. Estimation of Survival Distributions of Treatment Policies in
Two-Stage Randomization Designs in Clinical Trials. Biometrics 2002, 58, 48–57. [CrossRef] [PubMed]
17. Panuccio, G.; Guez, A.; Vincent, R.; Avoli, M.; Pineau, J. Adaptive control of epileptiform excitability in an
in vitro model of limbic seizures. Exp. Neurol. 2013, 241, 179–183. [CrossRef] [PubMed]
18. Topol, E.J. High-performance medicine: The convergence of human and artificial intelligence. Nat. Med.
2019, 25, 44–56. [CrossRef]
19. Sayers, E. A General Introduction to the E-utilities; National Center for Biotechnology Information (US):
Bethesda, MD, USA, 2010.
20. Cock, P.J.A.; Antao, T.; Chang, J.T.; Chapman, B.A.; Cox, C.J.; Dalke, A.; Friedberg, I.; Hamelryck, T.; Kauff, F.;
Wilczynski, B.; et al. Biopython: Freely available Python tools for computational molecular biology and
bioinformatics. Bioinformatics 2009, 25, 1422–1423. [CrossRef]
Genes 2019, 10, 978 20 of 24
21. Carter, H.; Douville, C.; Stenson, P.D.; Cooper, D.N.; Karchin, R. Identifying Mendelian disease genes with
the Variant Effect Scoring Tool. BMC Genom. 2013, 14, S3. [CrossRef]
22. Alirezaie, N.; Kernohan, K.D.; Hartley, T.; Majewski, J.; Hocking, T.D. ClinPred: Prediction Tool to Identify
Disease-Relevant Nonsynonymous Single-Nucleotide Variants. Am. J. Hum. Genet. 2018, 103, 474–483.
[CrossRef]
23. Bosio, M.; Drechsel, O.; Rahman, R.; Muyas, F.; Rabionet, R.; Bezdan, D.; Domenech Salgado, L.; Hor, H.;
Schott, J.; Munell, F.; et al. eDiVA—Classification and prioritization of pathogenic variants for clinical
diagnostics. Hum. Mutat. 2019, 40, 865–878. [CrossRef]
24. Sundaram, L.; Gao, H.; Padigepati, S.R.; McRae, J.F.; Li, Y.; Kosmicki, J.A.; Fritzilas, N.; Hakenberg, J.;
Dutta, A.; Shon, J.; et al. Predicting the clinical impact of human mutation with deep neural networks.
Nat. Genet. 2018, 50, 1161–1170. [CrossRef]
25. Dehiya, V.; Thomas, J.; Sael, L. Impact of structural prior knowledge in SNV prediction: Towards causal
variant finding in rare disease. PLoS ONE 2018, 13, e0204101. [CrossRef] [PubMed]
26. Buske, O.J.; Manickaraj, A.; Mital, S.; Ray, P.N.; Brudno, M. Identification of deleterious synonymous variants
in human genomes. Bioinformatics 2013, 29, 1843–1850. [CrossRef] [PubMed]
27. Browne, C.; Timson, D.J. In Silico Prediction of the Effects of Mutations in the Human Mevalonate Kinase
Gene: Towards a Predictive Framework for Mevalonate Kinase Deficiency: Effects of Mutations in Human
MVK. Ann. Hum. Genet. 2015, 79, 451–459. [CrossRef] [PubMed]
28. Orange, J.S.; Glessner, J.T.; Resnick, E.; Sullivan, K.E.; Lucas, M.; Ferry, B.; Kim, C.E.; Hou, C.; Wang, F.;
Chiavacci, R.; et al. Genome-wide association identifies diverse causes of common variable immunodeficiency.
J. Allergy Clin. Immunol. 2011, 127, 1360–1367.e6. [CrossRef] [PubMed]
29. Jaganathan, K.; Kyriazopoulou Panagiotopoulou, S.; McRae, J.F.; Darbandi, S.F.; Knowles, D.; Li, Y.I.;
Kosmicki, J.A.; Arbelaez, J.; Cui, W.; Schwartz, G.B.; et al. Predicting Splicing from Primary Sequence with
Deep Learning. Cell 2019, 176, 535–548.e24. [CrossRef]
30. Papadimitriou, S.; Gazzo, A.; Versbraegen, N.; Nachtegael, C.; Aerts, J.; Moreau, Y.; Van Dooren, S.; Nowé, A.;
Smits, G.; Lenaerts, T. Predicting disease-causing variant combinations. Proc. Natl. Acad. Sci. USA 2019,
116, 11878–11887. [CrossRef]
31. Yang, X.; Song, Z.; Wu, C.; Wang, W.; Li, G.; Zhang, W.; Wu, L.; Lu, K. Constructing a database for the
relations between CNV and human genetic diseases via systematic text mining. BMC Bioinform. 2018, 19, 528.
[CrossRef]
32. Boudellioua, I.; Kulmanov, M.; Schofield, P.N.; Gkoutos, G.V.; Hoehndorf, R. DeepPVP: Phenotype-based
prioritization of causative variants using deep learning. BMC Bioinform. 2018, 20, 65. [CrossRef]
33. Li, Q.; Zhao, K.; Bustamante, C.D.; Ma, X.; Wong, W.H. Xrare: A machine learning method jointly modeling
phenotypes and genetic evidence for rare disease diagnosis. Genet. Med. 2019, 21, 2126–2134. [CrossRef]
34. Rao, A.; Vg, S.; Joseph, T.; Kotte, S.; Sivadasan, N.; Srinivasan, R. Phenotype-driven gene prioritization
for rare diseases using graph convolution on heterogeneous networks. BMC Med. Genom. 2018, 11, 57.
[CrossRef]
35. Paul, R.; Groza, T.; Hunter, J.; Zankl, A. Inferring characteristic phenotypes via class association rule mining
in the bone dysplasia domain. J. Biomed. Inform. 2014, 48, 73–83. [CrossRef] [PubMed]
36. Ehsani-Moghaddam, B.; Queenan, J.A.; MacKenzie, J.; Birtwhistle, R.V. Mucopolysaccharidosis type II
detection by Naïve Bayes Classifier: An example of patient classification for a rare disease using electronic
medical records from the Canadian Primary Care Sentinel Surveillance Network. PLoS ONE 2018, 13, e0209018.
[CrossRef] [PubMed]
37. Shen, F.; Liu, S.; Wang, Y.; Wen, A.; Wang, L.; Liu, H. Utilization of Electronic Medical Records and
Biomedical Literature to Support the Diagnosis of Rare Diseases Using Data Fusion and Collaborative
Filtering Approaches. JMIR Med. Inform. 2018, 6, e11301. [CrossRef]
38. Shen, F.; Zhao, Y.; Wang, L.; Mojarad, M.R.; Wang, Y.; Liu, S.; Liu, H. Rare disease knowledge enrichment
through a data-driven approach. BMC Med Inform. Decis. Mak. 2019, 19, 32. [CrossRef]
39. Javed, A.; Agrawal, S.; Ng, P.C. Phen-Gen: Combining phenotype and genotype to analyze rare disorders.
Nat. Methods 2014, 11, 935–937. [CrossRef]
40. Garcelon, N.; Neuraz, A.; Salomon, R.; Faour, H.; Benoit, V.; Delapalme, A.; Munnich, A.; Burgun, A.;
Rance, B. A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse. J. Biomed.
Inform. 2018, 80, 52–63. [CrossRef]
Genes 2019, 10, 978 21 of 24
41. Garcelon, N.; Neuraz, A.; Benoit, V.; Salomon, R.; Kracker, S.; Suarez, F.; Bahi-Buisson, N.; Hadj-Rabia, S.;
Fischer, A.; Munnich, A.; et al. Finding patients using similarity measures in a rare diseases-oriented clinical
data warehouse: Dr. Warehouse and the needle in the needle stack. J. Biomed. Inform. 2017, 73, 51–61.
[CrossRef]
42. Smpokou, P.; Lanpher, B.C.; Rosenbaum, K.N. Important Considerations in the Initial Clinical Evaluation of
the Dysmorphic Neonate. Adv. Neonatal Care 2015, 15, 248–252. [CrossRef]
43. Smith, K.; Piccinini, F.; Balassa, T.; Koos, K.; Danka, T.; Azizpour, H.; Horvath, P. Phenotypic Image Analysis
Software Tools for Exploring and Understanding Big Image Data from Cell-Based Assays. Cell Syst. 2018,
6, 636–653. [CrossRef]
44. Gurovich, Y.; Hanani, Y.; Bar, O.; Nadav, G.; Fleischer, N.; Gelbman, D.; Basel-Salmon, L.; Krawitz, P.M.;
Kamphausen, S.B.; Zenker, M.; et al. Identifying facial phenotypes of genetic disorders using deep learning.
Nat. Med. 2019, 25, 60–64. [CrossRef]
45. LeCun, Y.; Bengio, Y.; Hinton, G. Deep learning. Nature 2015, 521, 436–444. [CrossRef] [PubMed]
46. Zarate, Y.A.; Smith-Hicks, C.L.; Greene, C.; Abbott, M.-A.; Siu, V.M.; Calhoun, A.R.U.L.; Pandya, A.; Li, C.;
Sellars, E.A.; Kaylor, J.; et al. Natural history and genotype-phenotype correlations in 72 individuals with
SATB2 -associated syndrome. Am. J. Med. Genet. 2018, 176, 925–935. [CrossRef] [PubMed]
47. Basel-Vanagaite, L.; Wolf, L.; Orin, M.; Larizza, L.; Gervasini, C.; Krantz, I.D.; Deardoff, M.A. Recognition of
the Cornelia de Lange syndrome phenotype with facial dysmorphology novel analysis: Recognition of the
CdLS Phenotype with FDNA. Clin. Genet. 2016, 89, 557–563. [CrossRef] [PubMed]
48. Liehr, T.; Acquarola, N.; Pyle, K.; St-Pierre, S.; Rinholm, M.; Bar, O.; Wilhelm, K.; Schreyer, I. Next generation
phenotyping in Emanuel and Pallister-Killian syndrome using computer-aided facial dysmorphology
analysis of 2D photos: LIEHR et al. Clin. Genet. 2018, 93, 378–381. [CrossRef] [PubMed]
49. Marbach, F.; Rustad, C.F.; Riess, A.; Đukic´, D.; Hsieh, T.-C.; Jobani, I.; Prescott, T.; Bevot, A.; Erger, F.;
Houge, G.; et al. The Discovery of a LEMD2-Associated Nuclear Envelopathy with Early Progeroid
Appearance Suggests Advanced Applications for AI-Driven Facial Phenotyping. Am. J. Hum. Genet. 2019,
104, 749–757. [CrossRef]
50. Learned-Miller, E.; Lu, Q.; Paisley, A.; Trainer, P.; Blanz, V.; Dedden, K.; Miller, R. Detecting Acromegaly:
Screening for Disease with a Morphable Model. In Medical Image Computing and Computer-Assisted
Intervention—MICCAI 2006; Larsen, R., Nielsen, M., Sporring, J., Eds.; Springer: Heidelberg, Germany, 2006;
Volume 4191, pp. 495–503. ISBN 978-3-540-44727-6.
51. Spinelli, E.G.; Mandelli, M.L.; Miller, Z.A.; Santos-Santos, M.A.; Wilson, S.M.; Agosta, F.; Grinberg, L.T.;
Huang, E.J.; Trojanowski, J.Q.; Meyer, M.; et al. Typical and atypical pathology in primary progressive
aphasia variants: Pathology in PPA Variants. Ann Neurol. 2017, 81, 430–443. [CrossRef]
52. Hsieh, T.-C.; Mensah, M.A.; Pantel, J.T.; Aguilar, D.; Bar, O.; Bayat, A.; Becerra-Solano, L.; Bentzen, H.B.;
Biskup, S.; Borisov, O.; et al. PEDIA: Prioritization of exome data by image analysis. Genet. Med. 2019.
[CrossRef]
53. Lux, A.; Müller, R.; Tulk, M.; Olivieri, C.; Zarrabeita, R.; Salonikios, T.; Wirnitzer, B. HHT diagnosis by
Mid-infrared spectroscopy and artificial neural network analysis. Orphanet J. Rare Dis. 2013, 8, 94. [CrossRef]
[PubMed]
54. Han, I.; Kim, J.H.; Park, H.; Kim, H.-S.; Seo, S.W. Deep learning approach for survival prediction for patients
with synovial sarcoma. Tumour Biol. 2018, 40, 101042831879926. [CrossRef]
55. Van IJzendoorn, D.G.P.; Szuhai, K.; Briaire-de Bruijn, I.H.; Kostine, M.; Kuijjer, M.L.; Bovée, J.V.M.G. Machine
learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies
therapeutic targets for soft tissue sarcomas. PLoS Comput. Biol. 2019, 15, e1006826. [CrossRef]
56. Noto, K.; Majidi, S.; Edlow, A.G.; Wick, H.C.; Bianchi, D.W.; Slonim, D.K. CSAX: Characterizing Systematic
Anomalies in eXpression Data. J. Comput. Biol. 2015, 22, 402–413. [CrossRef] [PubMed]
57. Taroni, J.N.; Grayson, P.C.; Hu, Q.; Eddy, S.; Kretzler, M.; Merkel, P.A.; Greene, C.S. MultiPLIER: A Transfer
Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease. Cell Syst. 2019,
8, 380–394.e4. [CrossRef] [PubMed]
58. DeAndrés-Galiana, E.J.; Fernández-Martínez, J.L.; Sonis, S.T. Design of Biomedical Robots for Phenotype
Prediction Problems. J. Comput. Biol. 2016, 23, 678–692. [CrossRef] [PubMed]
59. DeAndrés-Galiana, E.J.; Fernández-Martínez, J.L.; Sonis, S.T. Sensitivity analysis of gene ranking methods in
phenotype prediction. J. Biomed. Inform. 2016, 64, 255–264. [CrossRef] [PubMed]
Genes 2019, 10, 978 22 of 24
60. Romero, R.; Ramanathan, A.; Yuen, T.; Bhowmik, D.; Mathew, M.; Munshi, L.B.; Javaid, S.; Bloch, M.;
Lizneva, D.; Rahimova, A.; et al. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher
disease unraveled by molecular dynamics and deep learning. Proc. Natl. Acad. Sci. USA 2019, 116, 5086–5095.
[CrossRef]
61. Danter, W.R. DeepNEU: Cellular reprogramming comes of age – a machine learning platform with application
to rare diseases research. Orphanet J. Rare Dis. 2019, 14, 13. [CrossRef]
62. Hoehndorf, R.; Schofield, P.N.; Gkoutos, G.V. Analysis of the human diseasome using phenotype similarity
between common, genetic and infectious diseases. Sci. Rep. 2015, 5, 10888. [CrossRef]
63. Lee, Y.; Krishnan, A.; Oughtred, R.; Rust, J.; Chang, C.S.; Ryu, J.; Kristensen, V.N.; Dolinski, K.; Theesfeld, C.L.;
Troyanskaya, O.G. A Computational Framework for Genome-wide Characterization of the Human Disease
Landscape. Cell Syst. 2019, 8, 152–162. [CrossRef]
64. Crow, R.A.; Hart, K.A.; McDermott, M.P.; Tawil, R.; Martens, W.B.; Herr, B.E.; McColl, E.; Wilkinson, J.;
Kirschner, J.; King, W.M.; et al. A checklist for clinical trials in rare disease: Obstacles and anticipatory
actions—lessons learned from the FOR-DMD trial. Trials 2018, 19, 291. [CrossRef]
65. Day, S.; Jonker, A.H.; Lau, L.P.L.; Hilgers, R.-D.; Irony, I.; Larsson, K.; Roes, K.C.; Stallard, N. Recommendations
for the design of small population clinical trials. Orphanet J. Rare Dis. 2018, 13, 195. [CrossRef]
66. Logviss, K.; Krievins, D.; Purvina, S. Characteristics of clinical trials in rare vs. common diseases:
A register-based Latvian study. PLoS ONE 2018, 13, e0194494. [CrossRef] [PubMed]
67. Geva, A.; Gronsbell, J.L.; Cai, T.; Cai, T.; Murphy, S.N.; Lyons, J.C.; Heinz, M.M.; Natter, M.D.; Patibandla, N.;
Bickel, J.; et al. A Computable Phenotype Improves Cohort Ascertainment in a Pediatric Pulmonary
Hypertension Registry. J. Pediatrics 2017, 188, 224–231.e5. [CrossRef] [PubMed]
68. Lochmüller, H.; Torrent i Farnell, J.; Le Cam, Y.; Jonker, A.H.; Lau, L.P.; Baynam, G.; Kaufmann, P.;
Dawkins, H.J.; Lasko, P.; Austin, C.P.; et al. The International Rare Diseases Research Consortium: Policies
and Guidelines to maximize impact. Eur. J. Hum. Genet. 2017, 25, 1293–1302. [CrossRef] [PubMed]
69. Ganesalingam, J.; Bowser, R. The application of biomarkers in clinical trials for motor neuron disease.
Biomark. Med. 2010, 4, 281–297. [CrossRef] [PubMed]
70. Blasco, H.; Patin, F.; Descat, A.; Garçon, G.; Corcia, P.; Gelé, P.; Lenglet, T.; Bede, P.; Meininger, V.;
Devos, D.; et al. A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive
markers of progression. PLoS ONE 2018, 13, e0198116. [CrossRef] [PubMed]
71. Lagrue, E.; Madji Hounoum, B.; Rullier, C.R.; Andres, C.; Emond, P.; Bocca, C.; Castelnau, P.; Blasco, H.
Cerebrospinal fluid metabolomics in West Syndrome: Central role of the serine metabolic pathway.
J. Transl. Sci. 2018, 4, e101. [CrossRef]
72. Carlier, A.; Vasilevich, A.; Marechal, M.; de Boer, J.; Geris, L. In silico clinical trials for pediatric orphan
diseases. Sci. Rep. 2018, 8, 2465. [CrossRef]
73. Catling, F.; Spithourakis, G.P.; Riedel, S. Towards automated clinical coding. Int. J. Med Inform. 2018, 120, 50–61.
[CrossRef]
74. Bhasuran, B.; Murugesan, G.; Abdulkadhar, S.; Natarajan, J. Stacked ensemble combined with fuzzy matching
for biomedical named entity recognition of diseases. J. Biomed. Inform. 2016, 64, 1–9. [CrossRef]
75. Xu, K.; Yang, Z.; Kang, P.; Wang, Q.; Liu, W. Document-level attention-based BiLSTM-CRF incorporating
disease dictionary for disease named entity recognition. Comput. Biol. Med. 2019, 108, 122–132. [CrossRef]
76. Santoro, M.; Coi, A.; Lipucci Di Paola, M.; Bianucci, A.M.; Gainotti, S.; Mollo, E.; Taruscio, D.; Vittozzi, L.;
Bianchi, F. Rare Disease Registries Classification and Characterization: A Data Mining Approach. Public Health
Genom. 2015, 18, 113–122. [CrossRef]
77. Péanne, R.; de Lonlay, P.; Foulquier, F.; Kornak, U.; Lefeber, D.J.; Morava, E.; Pérez, B.; Seta, N.; Thiel, C.;
Van Schaftingen, E.; et al. Congenital disorders of glycosylation (CDG): Quo vadis? Eur. J. Med. Genet. 2018,
61, 643–663. [CrossRef] [PubMed]
78. Jaeken, J.; Péanne, R. What is new in CDG? J. Inherit. Metab. Dis. 2017, 40, 569–586. [CrossRef]
79. Francisco, R.; Marques-da-Silva, D.; Brasil, S.; Pascoal, C.; dos Reis Ferreira, V.; Morava, E.; Jaeken, J.
The challenge of CDG diagnosis. Mol. Genet. Metab. 2019, 126, 1–5. [CrossRef]
80. Pascoal, C.; Francisco, R.; Ferro, T.; dos Reis Ferreira, V.; Jaeken, J.; Videira, P.A. CDG and immune response:
From bedside to bench and back. J. Inherit. Metab. Dis. 2019. [CrossRef]
Genes 2019, 10, 978 23 of 24
81. Citro, V.; Cimmaruta, C.; Monticelli, M.; Riccio, G.; Hay Mele, B.; Cubellis, M.; Andreotti, G. The Analysis
of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations
and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers. Int. J. Mol. Sci. 2018,
19, 2218. [CrossRef] [PubMed]
82. Caragea, C.; Sinapov, J.; Silvescu, A.; Dobbs, D.; Honavar, V. Glycosylation site prediction using ensembles of
Support Vector Machine classifiers. BMC Bioinform. 2007, 8, 438. [CrossRef]
83. Hamby, S.E.; Hirst, J.D. Prediction of glycosylation sites using random forests. BMC Bioinform. 2008, 9, 500.
[CrossRef]
84. Brasil, S.; Pascoal, C.; Francisco, R.; Marques-da-Silva, D.; Andreotti, G.; Videira, P.; Morava, E.; Jaeken, J.;
dos Reis Ferreira, V. CDG Therapies: From Bench to Bedside. Int. J. Mol. Sci. 2018, 19, 1304. [CrossRef]
85. Ng, B.G.; Freeze, H.H. Perspectives on Glycosylation and Its Congenital Disorders. Trends Genet. 2018,
34, 466–476. [CrossRef]
86. Blackburn, J.B.; D’Souza, Z.; Lupashin, V.V. Maintaining order: COG complex controls Golgi trafficking,
processing, and sorting. FEBS Lett. 2019, 593, 2466–2487. [CrossRef] [PubMed]
87. Marquardt, T.; Freeze, H. Congenital Disorders of Glycosylation: Glycosylation Defects in Man and Biological
Models for Their Study. Biol. Chem. 2001, 382, 161–177. [CrossRef] [PubMed]
88. Blackburn, J.B.; Kudlyk, T.; Pokrovskaya, I.; Lupashin, V.V. More than just sugars: Conserved oligomeric Golgi
complex deficiency causes glycosylation-independent cellular defects. Traffic 2018, 19, 463–480. [CrossRef]
[PubMed]
89. Rahman, M.S.; Rahman, M.K.; Kaykobad, M.; Rahman, M.S. isGPT: An optimized model to identify sub-Golgi
protein types using SVM and Random Forest based feature selection. Artif. Intell. Med. 2018, 84, 90–100.
[CrossRef]
90. Martinez-Monseny, A.; Cuadras, D.; Bolasell, M.; Muchart, J.; Arjona, C.; Borregan, M.; Algrabli, A.;
Montero, R.; Artuch, R.; Velázquez-Fragua, R.; et al. From gestalt to gene: Early predictive dysmorphic
features of PMM2-CDG. J. Med. Genet. 2019, 56, 236–245. [CrossRef]
91. Jia, J.; Wang, R.; An, Z.; Guo, Y.; Ni, X.; Shi, T. RDAD: A Machine Learning System to Support Phenotype-Based
Rare Disease Diagnosis. Front. Genet. 2018, 9, 587. [CrossRef]
92. Mordenti, M.; Ferrari, E.; Pedrini, E.; Fabbri, N.; Campanacci, L.; Muselli, M.; Sangiorgi, L. Validation of a
new multiple osteochondromas classification through Switching Neural Networks. Am. J. Med. Genet. 2013,
161, 556–560. [CrossRef]
93. Freeze, H.H.; Eklund, E.A.; Ng, B.G.; Patterson, M.C. Neurology of inherited glycosylation disorders.
Lancet Neurol. 2012, 11, 453–466. [CrossRef]
94. Izquierdo-Serra, M.; Martínez-Monseny, A.; López, L.; Carrillo-García, J.; Edo, A.; Ortigoza-Escobar, J.;
García,Ó.; Cancho-Candela, R.; Carrasco-Marina, M.; Gutiérrez-Solana, L. Stroke-Like Episodes and Cerebellar
Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven
Channelopathy. Int. J. Mol. Sci. 2018, 19, 619. [CrossRef]
95. Hung, C.-Y.; Lin, C.-H.; Lee, C.-C. Improving Young Stroke Prediction by Learning with Active Data
Augmenter in a Large-Scale Electronic Medical Claims Database. In Proceedings of the 2018 40th Annual
International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Honolulu,
HI, USA, 17–21 July 2018; pp. 5362–5365.
96. Mears, A.J.; Schock, S.C.; Hadwen, J.; Putos, S.; Dyment, D.; Boycott, K.M.; MacKenzie, A. Mining the
transcriptome for rare disease therapies: A comparison of the efficiencies of two data mining approaches
and a targeted cell-based drug screen. npj Genom. Med. 2017, 2, 14. [CrossRef]
97. Wang, F.; Preininger, A. AI in Health: State of the Art, Challenges, and Future Directions. Yearb. Med. Inf.
2019, 28, 016–026. [CrossRef] [PubMed]
98. Conejar, R.J.; Kim, H.-K. A Medical Decision Support System (DSS) for Ubiquitous Healthcare Diagnosis
System. Int. J. Softw. Eng. Its Appl. 2014, 8, 8.
99. Jurmeister, P.; Schöler, A.; Arnold, A.; Klauschen, F.; Lenze, D.; Hummel, M.; Schweizer, L.; Bläker, H.;
Pfitzner, B.M.; Mamlouk, S.; et al. DNA methylation profiling reliably distinguishes pulmonary enteric
adenocarcinoma from metastatic colorectal cancer. Mod. Pathol. 2019, 32, 855–865. [CrossRef]
100. Mücke, U.; Klemann, C.; Baumann, U.; Meyer-Bahlburg, A.; Kortum, X.; Klawonn, F.; Lechner, W.M.; Grigull, L.
Patient’s Experience in Pediatric Primary Immunodeficiency Disorders: Computerized Classification of
Questionnaires. Front. Immunol. 2017, 8, 384. [CrossRef] [PubMed]
Genes 2019, 10, 978 24 of 24
101. Mavris, M.; Le Cam, Y. Involvement of Patient Organisations in Research and Development of Orphan Drugs
for Rare Diseases in Europe. Mol. Syndr. 2012, 3, 237–243. [CrossRef]
102. Subirats, L.; Reguera, N.; Bañón, A.; Gómez-Zúñiga, B.; Minguillón, J.; Armayones, M. Mining Facebook Data
of People with Rare Diseases: A Content-Based and Temporal Analysis. Int. J. Environ. Res. Public Health
2018, 15, 1877. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
